Page last updated: 2024-09-03

gefitinib and Fatigue

gefitinib has been researched along with Fatigue in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's5 (55.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K1
Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J1
Giaccone, G; Hoekman, K; Jürgensmeier, JM; Meijerink, MR; Puchalski, TA; Punt, CJ; Robertson, J; Saunders, O; van Cruijsen, H; van Herpen, CM; Voest, EE; Witteveen, PO1
Daga, H; Hirashima, T; Hirata, K; Kawaguchi, T; Kimura, T; Kobayashi, M; Kudoh, S; Mitsuoka, S; Okishio, K; Takeda, K; Yoshimura, N1
Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC1
Baetz, T; Berry, S; Brundage, M; Canil, CM; Chi, KN; Douglas, L; Ernst, DS; Fisher, B; McKenna, A; Moore, MJ; Pollak, M; Seymour, L; Winquist, E1
Ceribelli, A; Cognetti, F; Gelibter, A; Milella, M; Moscetti, L; Pollera, CF; Sperduti, I1
Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J1
Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J1

Trials

9 trial(s) available for gefitinib and Fatigue

ArticleYear
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome

2013
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment

2014
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:5

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Therapy, Combination; ErbB Receptors; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Netherlands; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult

2010
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:1

    Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Protein Kinase Inhibitors; Quinazolines

2013
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy

2013
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines

2005
Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer.
    Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Constipation; Disease Progression; Dyspnea; Fatigue; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Survival Analysis; Treatment Outcome

2005
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
    Lung cancer (Amsterdam, Netherlands), 2006, Volume: 52, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur

2006
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
    Onkologie, 2006, Volume: 29, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome

2006